Abstract
Idiopathic intracranial hypertension is characterized by raised intracranial pressure that triggers disabling headaches and can cause permanent visual loss. There is an increased incidence and prevalence of the condition linked to location-specific obesity rates. There are no licensed treatments for the condition. The majority of approaches to managing the disease prioritize resolution of papilledema. However, evidence is emerging that idiopathic intracranial hypertension is a systemic metabolic disease.
Original language | English |
---|---|
Journal | Expert Review of Neurotherapeutics |
Early online date | 28 Apr 2023 |
DOIs | |
Publication status | E-pub ahead of print - 28 Apr 2023 |